MINT-CLONIDINE 0.025 MG — DIN 02534738
CLONIDINE HYDROCHLORIDE : 0.025 MG · MINT PHARMACEUTICALS INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is MINT-CLONIDINE?
MINT-CLONIDINE 0.025 MG contains CLONIDINE HYDROCHLORIDE : 0.025 MG. It is listed in the Health Canada Drug Product Database under DIN 02534738, held by MINT PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 10-May-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MINT-CLONIDINE used for?
MINT-CLONIDINE (clonidine hydrochloride) is indicated for the relief of menopausal flushing in patients for whom hormonal replacement therapy is either unnecessary or not desirable.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Clonidine cost around the world?
Clonidine is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 6 | 83 |
| Australia | ex-manufacturer | 4 | 8 |
| Iceland | max wholesale | 6 | 8 |
| South Africa | single exit price | 2 | 3 |
| United Kingdom | hospital | 2 | 2 |
| Greece | producer price (ex-factory) | 1 | 1 |
| Morocco | PPV (public price) | 1 | 1 |
106 pack listings across 22 brand entries and 7 price bases, refreshed 10 Sep 2026. Ranges span every Clonidine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Clonidine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Clonidine, across 31 DINs, of which 14 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 6 | 3 | NTP-CLONIDINE, TEVA-CLONIDINE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 3 | 3 | MINT-CLONIDINE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 3 | SANDOZ CLONIDINE | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 3 | 3 | CLONIDINE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP CLONIDINE | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | MAR-CLONIDINE | Sourceable in Canada |
| APOTEX INC | 3 | 0 | APO-CLONIDINE, APO-CLONIDINE TAB 0.1MG, APO-CLONIDINE TAB 0.2MG | No marketed DIN |
| SANIS HEALTH INC | 3 | 0 | CLONIDINE | No marketed DIN |
| BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 2 | 0 | CATAPRES TAB 0.1MG, CATAPRES TAB 0.2MG | No marketed DIN |
| DOMINION PHARMACAL | 2 | 0 | DOM-CLONIDINE | No marketed DIN |
| NU-PHARM INC | 2 | 0 | NU-CLONIDINE TAB 0.1MG, NU-CLONIDINE TAB 0.2MG | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | CLONIDINE 0.1, CLONIDINE HCL TAB 0.2MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.025 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 0.025 mg tablet: Round, blue colored, biconvex coated tablet, debossed “0.025” on one side and plain on the other side. MINT-CLONIDINE 0.025 mg tablets are supplied in bottles of 100 tablets. |
| Storage | MINT-CLONIDINE tablets should be stored between 15°C -30°C. Protect from moisture. Keep this medicine out of the sight and reach of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Clonidine |
|---|---|
| ATC code | C02AC01 |
| AHFS class | 48:08.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02534738 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2534738 |
| Brand name | MINT-CLONIDINE |
| Generic / active ingredient | CLONIDINE HYDROCHLORIDE : 0.025 MG |
| Market authorization holder | MINT PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | C02AC01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C02AC |
| Current status | MARKETED |
| Status date | 10-May-2023 |
| Original market date | 2024-06-03 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Recommended Dose and Dosage Adjustment: The recommended dose for the treatment of menopausal flushing is 0.05 mg of MINT-CLONIDINE (clonidine hydrochloride) twice daily. If after two to four weeks there has been no remission, the treatment should be discontinued and the patient reassessed. Attempts should be made to discontinue treatment at three to six month intervals for patient re-evaluation of menopausal symptoms. Following sudden discontinuation of clonidine hydrochloride after prolonged treatment with high doses, restlessness, palpitations, rapid rise in blood pressure, nervousness, tremor, headache or nausea have been reported. When discontinuing therapy with MINT-CLONIDINE, the physician should reduce the dose gradually over 2-4 days. Missed Dose: If a dose of MINT-CLONIDINE is missed, patients should take the dose as soon as possible and then return to their normal schedule. Administration: The tablets should be swallowed whole with water.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
MINT-CLONIDINE (clonidine hydrochloride) is contraindicated in patients with the following: • know hypersensitivity to the active substance or to any of the ingredients of the product. • severe bradyarrhythmia resulting from either sick sinus syndrome or atrioventricular block of 2nd or 3rd degree; patients with sinus node function impairment. • rare hereditary conditions that may be incompatible with an excipient of the product. This product contains 235.1 mg of lactose per maximum recommended daily dose. Patients with the rare hereditary conditions of galactose intolerance e.g. galactosaemia should not take this medicine.
Warnings and precautions
An abrupt withdrawal of higher doses of clonidine hydrochloride is followed in some cases by an excess of circulating catecholamines. Therefore, caution should be exercised in concomitant use of drugs which affect the metabolism, tissue uptake or pressor effects of these amines (monoamine oxidase inhibitors, tricyclic antidepressants and beta-blocking agents). MINT-CLONIDINE (clonidine hydrochloride 0.025 mg) should not be confused with higher strength dosage forms containing the same active ingredient (clonidine hydrochloride 0.1 mg or 0.2 mg) used for treating hypertension. Caution should however be exercised in patients receiving antihypertensive therapy because of the possibility of an additive effect. Note: MINT-CLONIDINE is only available in a 0.025 mg strength tablet. Patients who engage in potentially hazardous activities such as operating machinery or driving should be warned of the possible sedative effect of clonidine hydrochloride. Caution should be exercised in the concomitant administration of sedatives, tranquilizing drugs or alcohol. Patients should be instructed not to discontinue therapy without consulting their physician. Clonidine hydrochloride can have a hypotensive effect especially in high doses. In patients whose blood pressure decreases to an intolerable extent when taking MINT- CLONIDINE, treatment should be discontinued. An excessive rise in blood pressure following discontinuation of MINT-CLONIDINE therapy can be reversed by intravenous phentolamine. Because it can lower blood pressure at high doses, MINT-CLONIDINE (clonidine hydrochloride) should be used with caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebral vascular disease, or chronic renal failure. MINT-CLONIDINE should be used with caution in patients with mild to moderate bradyarrhythmia such as low sinus rhythm, with disorders of cerebral or peripheral perfusion, polyneuropathy, and constipation, patients with heart failure or severe coronary heart disease. Depending on the dose given, MINT-CLONIDINE can lower the heart and pulse rate. In patients with diseases affecting the rhythmic and atrioventricular conduction system of the heart, arrhythmias have been observed after high doses. Patients with heart failure or severe coronary disease should be monitored particularly carefully when using MINT-CLONIDINE. A few instances of a condition resembling Raynaud's phenomenon have been reported with the higher doses of clonidine as used in the therapy of hypertension. Caution should be observed if patients with Raynaud's disease or thromboangiitis obliterans are to be treated with MINT-CLONIDINE. In several studies clonidine hydrochloride produced a dose-dependent increase in the incidence and severity of spontaneously occurring retinal degeneration in albino rats treated for six months or longer. In view of this retinal degeneration, eye examinations were performed in 908 hypertensive patients prior to the start of clonidine hydrochloride therapy, who were then examined periodically thereafter. In 353 of these 908 patients, examinations were performed for periods of 24 months or longer. Except for the dryness of the eyes, no drug-related abnormal ophthalmologic findings were recorded and clonidine hydrochloride did not alter retinal function as shown by specialized tests such as the electroretinogram and macular dazzle. Patients who wear contact lenses should be warned that treatment with MINT-CLONIDINE may cause decreased lacrimation. Patients with a known history of depression should be carefully supervised while under treatment with clonidine as there have been occasional reports of further depressive episodes occurring in such patients. Clonidine and its metabolites are extensively excreted with urine. As a result, MINT-CLONIDINE should be used with caution in patients with renal insufficiency. Careful monitoring of blood pressure is required. As with any drug excreted primarily in the urine, smaller
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
14 of 31 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLONIDINE | 0.1 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02538490 |
| CLONIDINE | 0.2 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02538504 |
| CLONIDINE | 0.025 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02540061 |
| JAMP CLONIDINE | 0.025 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02528207 |
| MAR-CLONIDINE | 0.025 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02524198 |
| MINT-CLONIDINE | 0.1 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02462192 |
| MINT-CLONIDINE | 0.2 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02462206 |
| SANDOZ CLONIDINE | 0.025 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02516217 |
| SANDOZ CLONIDINE | 0.2 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02515792 |
| SANDOZ CLONIDINE | 0.1 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02515784 |
2 · Same class — other molecules in ATC C02AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Guanfacine | AG-GUANFACINE XR · APO-GUANFACINE XR · INTUNIV XR · JAMP GUANFACINE XR · +1 more | 19 | 19 | Yes |
| Clonidine | APO-CLONIDINE · APO-CLONIDINE TAB 0.1MG · APO-CLONIDINE TAB 0.2MG · CATAPRES TAB 0.1MG · +13 more | 31 | 14 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C02AB | Methyldopa (Levorotatory) · Methyldopa (Racemic) | 23 | 3 |
| C02AA | Reserpine | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MINT-CLONIDINE called?
Also recorded in Canada as: 12 HR clonidine hydrochloride 0.1 MG Extended Release Oral Tablet [Kapvay] (US), 24 HR clonidine hydrochloride 0.1 MG/ML Extended Release Suspension [Onyda] (US), clonidine hydrochloride 0.02 MG/ML Oral Solution [Javadin] (US), 10 ML clonidine hydrochloride 0.1 MG/ML Injection [Duraclon] (US), 12 HR clonidine hydrochloride 0.1 MG Extended Release Oral Tablet (US), 24 HR clonidine hydrochloride 0.1 MG/ML Extended Release Suspension (US), clonidine hydrochloride 0.02 MG/ML Oral Solution (US), clonidine hydrochloride 0.05 MG Oral Tablet (US), clonidine hydrochloride 0.1 MG Oral Tablet (US), clonidine hydrochloride 0.2 MG Oral Tablet (US), clonidine hydrochloride 0.3 MG Oral Tablet (US), chlorthalidone 15 MG / clonidine hydrochloride 0.2 MG Oral Tablet (US), chlorthalidone 15 MG / clonidine hydrochloride 0.3 MG Oral Tablet (US), 10 ML clonidine hydrochloride 0.1 MG/ML Injection (US), 10 ML clonidine hydrochloride 0.5 MG/ML Injection (US).
The same molecule, Clonidine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Clonidine | Latin | Australia |
| Catapres | Latin | Australia |
| Catapresan | Latin | Iceland |
| Clonidine Lupin | Latin | Australia |
| Menograine | Latin | South Africa |
| Catapresan (Distica) | Latin | Iceland |
| CATAPRESSAN | Latin | Morocco |
| Clonidin Ratiopharm | Latin | Iceland |
| Clonidine Hcl | Latin | Iceland |
| Dixarit | Latin | South Africa |
| Paracefan | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Clonidine called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Clonidine, published to help those searches reach this page.
| Language | Clonidine |
|---|---|
| Chinese (Simplified) 简体中文 | 可乐定 |
| Russian Русский | Клонидин |
| Korean 한국어 | 클로니딘 |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.